Filtered By:
Specialty: Research
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 257 results found since Jan 2013.

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Pradaxa < sup > ® < /sup > (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulability
Abstract The thrombin generation potential is an in vitro measure for the capacity of an individual to generate thrombin and recognized as a reflection of a hypo- or hypercoagulable status. Measurement of the in vivo thrombin activity, however, may be of clinical significance. We evaluated a new assay for in vivo thrombin activity and compared it to the in vitro thrombin generation potential in patients with hemophilia A (N = 15), oral anticoagulation for atrial fibrillation (AF) (N = 20), subjects with active cancer (N = 21), and healthy volunteers (N = 10). Thrombin activity was measured with a comme...
Source: Clinical and Experimental Medicine - April 18, 2016 Category: Research Source Type: research

Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation.
CONCLUSIONS: Significant differences in prevention of acute limb ischemia may exist between oral anticoagulant agents in patients with atrial fibrillation. Rivaroxaban lowers the risk of limb embolism versus warfarin, apixaban and dabigatran. PMID: 26949899 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 9, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
CONCLUSIONS: NVAF patients using different DOACs had different characteristics, including stroke and bleeding risks. Use of rivaroxaban, compared to apixaban was associated with significantly greater risk of bleeding-related readmissions across two database claims analyses. PMID: 26652179 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent.
CONCLUSIONS: TT, DT and DAPT displayed similar efficacy and safety. Although the superiority of OAC vs. DAPT for stroke prevention in AF patients has been demonstrated by previous randomized trials, a smaller frequency of high thromboembolic risks' features in DAPT group of the present study may have prevented the observation of a higher incidence of ischemic stroke in this group. PMID: 26767085 [PubMed]
Source: Clin Med Res - January 18, 2016 Category: Research Authors: De Vecchis R, Cantatrione C, Mazzei D Tags: J Clin Med Res Source Type: research

Postepy Hig Med Dosw 2015; 69:1505-1511 "Osteoprotegerin as a marker of atherosclerosis and a prognostic factor in stroke"
This article summarizes the current state of knowledge on the potential role of OPG as a biomarker and prognostic indicator of stroke.
Source: Postepy higieny i medycyny doswiadczalnej - January 15, 2016 Category: Research Tags: Review article Source Type: research

MicroRNA Regulatory Network Revealing the Mechanism of Inflammation in Atrial Fibrillation.
CONCLUSIONS In conclusion, the microRNA regulatory network sheds new light on the molecular mechanism of AF with this non-coding regulated model. PMID: 26567235 [PubMed - in process]
Source: Medical Science Monitor - November 20, 2015 Category: Research Tags: Med Sci Monit Source Type: research

Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice
Conclusions: The majority of stroke patients with AF in the clinical setting are considerably older than those included in clinical trials. While the distribution of vascular risk factors in clinical trials corresponds to proportions observed in clinical practice, an overrepresentation of the male sex in clinical trials is evident.
Source: BMC Research Notes - June 25, 2015 Category: Research Authors: Christian TanislavSonja MildeSabine SchwartzkopffBjörn MisselwitzNicole SiewekeManfred Kaps Source Type: research

Incidence of ischemic stroke or transient ischemic attack in patients with multiple risk factors with or without atrial fibrillation: a retrospective cohort study
Current Medical Research & Opinion, Ahead of Print.
Source: Current Medical Research and Opinion - May 6, 2015 Category: Research Tags: article Source Type: research

'Motion-Tracking' MRI Tests Reveal Novel Harbingers of Stroke in People with Common Heart Rhythm Disorder - 4/27/15
Stroke is a frequent and dreaded complication of atrial fibrillation. But predicting which of the estimated six million Americans with a-fib are at highest risk has long challenged physicians weighing stroke risk against the serious side effects posed by lifelong therapy with warfarin and other blood thinners.
Source: Johns Hopkins Medicine News - April 27, 2015 Category: Research Source Type: news

Similarity of patient characteristics and outcomes in consecutive data collection on stroke admissions over one month compared to longer periods
Conclusions: Stroke patients admitted in one month had largely indistinguishable characteristics and discharge outcomes to those admitted to the same trusts in three separate seasons and also over two years in this cohort.
Source: BMC Research Notes - June 6, 2014 Category: Research Authors: Chun KwokStanley MusgraveGill PriceGenevieve DaltonPhyo Myint Source Type: research

Left atrial appendage closure in a patient with atrial fibrillation after mechanical mitral valve replacement and cardio-embolic stroke despite effective oral anticoagulant therapy: a case report.
PMID: 24687618 [PubMed - as supplied by publisher]
Source: Clin Med Res - April 1, 2014 Category: Research Authors: Sedaghat A, Nickenig G, Hammerstingl C Tags: Clin Res Cardiol Source Type: research

Edoxaban Effective in Preventing Stroke, Reducing Bleeding and Cardiovascular Death in Patients With Atrial Fibrillation
New study demonstrates that high- and low-dose edoxaban were at least as effective in preventing stroke or systemic embolism (blood clot), while significantly reducing bleeding and cardiovascular death, compared to warfarin.
Source: BWH for Journalists - November 19, 2013 Category: Research Source Type: news